Navigation Links
iBio Announces New US Patent for iBioLaunch™ Technology

NEWARK, Del., Oct. 31, 2011 /PRNewswire/ -- iBio, Inc. (NYSE AMEX: IBIO) today announced notice of issuance from the United States Patent and Trademark Office for US Patent 8,058,511, entitled "System for Expression of Genes in Plants," that further extends iBio's patent coverage of viral vectors comprising its iBioLaunch™ platform. This proprietary technology owned by iBio was developed by scientists at iBio's research collaborator, the Fraunhofer USA Center for Molecular Biotechnology (Fraunhofer).

"The issuance of this patent substantially strengthens the intellectual property foundation of the iBioLaunch system for simultaneously expressing more than a single protein," said Terence Ryan, Ph.D., iBio's Senior Vice-President. "For example, this patent protects the technology we use for production of human monoclonal antibodies, a rapidly growing pharmaceutical category in which we recently announced successful product candidate testing."

iBio is commercializing its technology by establishing licenses or other collaboration arrangements both for biosimilar products and proprietary products. In January 2011, iBio and Fraunhofer entered into a License and Collaboration Agreement with Fiocruz/ Bio-Manguinhos, an entity linked to the Health Ministry of Brazil, for the development and sale of a proprietary Yellow Fever Vaccine based upon the IBioLaunch technology, to replace the chicken egg based vaccine that Fiocruz has been producing and supplying to Brazil and more than 60 other nations. Since then, iBio has been advancing and making available other candidate products based on the iBioLaunch platform for similar license and collaboration arrangements.  

The broad range of iBioLaunch-produced product candidates in clinical or preclinical development include:  (i) human alpha-galactosidase for treatment of Fabry disease, (ii) the proteins C1 esterase inhibitor and alpha-1 antitrypsin which are currently derived from human blood plasma, (iii) monoclonal antibodies, and (iv) vaccines for prevention of yellow fever, influenza, malaria and anthrax. Additional undisclosed candidates are advancing through iBio's applications research program.

This additional iBio patent claims a system for expressing multiple polynucleotides of interest in a plant cell or whole plant using viral vectors that complement each other's viral functions in the plants.  The polynucleotides can encode chains of a multimeric protein, or can encode therapeutically active proteins.  The patent also describes methods for using the vector system to produce the desired proteins in plants.  Additional iBioLaunch vectors are described in iBio's earlier US patent 7,491,509 issued in 2009.

About iBio, Inc.

iBio develops and offers product applications of its iBioLaunch™ platform, providing collaborators full support for turn-key implementation of its technology for both proprietary and biosimilar products. The iBioLaunch platform is a proprietary, transformative technology for development and production of biologics using transient gene expression in unmodified green plants. The technology has been applied successfully to proteins difficult or impossible to produce with other methods, as well as proteins representative most important classes of biologic pharmaceuticals. Advantages of the iBioLaunch platform over other systems include enablement of rapid development and validation of modular, scalable, and optionally robotic, multi-product manufacturing facilities; production time measured in weeks instead of months or more; product entry that is unconstrained by traditional process patents; and significantly lower capital and operating costs for comparable production. Further information is available at:

Forward-Looking Statements

Statements included in this news release related to iBio, Inc. may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as lack of available capital, intellectual property protection issues, competitive factors, technological development, market demand, and the Company's ability to obtain new contracts and accurately estimate net revenues due to variability in size, scope and duration of projects. Further information on potential risk factors that could affect the Company's financial results can be found in the company's Reports filed with the Securities and Exchange Commission.



Robert Erwin, President
iBio, Inc.

Investor Contacts:

Douglas Beck, CFO
iBio, Inc.

SOURCE iBio, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
2. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
3. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
4. Anesiva Announces Second Quarter 2008 Financial Results and Update
5. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
6. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
7. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
8. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. ThirdBiotech Announces Kemeta as Newest Sponsor
10. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
11. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
Post Your Comments:
(Date:11/26/2015)... 26, 2015 --> ... in imaging technologies, announced today that it has received a ... the Horizon 2020 European Union Framework Programme for Research and ... trial in breast cancer. , --> ... --> --> The study aims to ...
(Date:11/25/2015)... 2015 Studies reveal the differences ... and pave the way for more effective treatment for one ...   --> --> ... problems in cats, yet relatively little was understood about the ... have been conducted by researchers from the WALTHAM Centre for ...
(Date:11/25/2015)... ... 25, 2015 , ... A long-standing partnership between the Academy ... been formalized with the signing of a Memorandum of Understanding. , AMA Executive ... Karl Minter and Capt. Albert Glenn Tuesday, November 24, 2015, at AMA Headquarters ...
(Date:11/24/2015)... LUMPUR, Malaysia , Nov. 24, 2015 /PRNewswire/ ... global contract research organisation (CRO) market. The trend ... result in lower margins but higher volume share ... increased capacity and scale, however, margins in the ... Research Organisation (CRO) Market ( ), ...
Breaking Biology Technology:
(Date:11/9/2015)... ) ... "Global Law Enforcement Biometrics Market 2015-2019" ... ) has announced the addition of ... 2015-2019" report to their offering. ... ) has announced the addition of the ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... , Oct. 29, 2015 Daon, a ... that it has released a new version of its ... in North America have already ... v4.0 also includes a FIDO UAF certified server ... already preparing to activate FIDO features. These customers include ...
Breaking Biology News(10 mins):